

PF 41(3) Table of Contents

Publish date: May 1, 2015

PROPOSED IRA

GENERAL CHAPTERS

[<87> BIOLOGICAL REACTIVITY TESTS, IN VITRO \(1-Sept-15\)](#)

USP MONOGRAPHS

[Powdered Digitalis \(1-Nov-15\)](#)

[Digoxin \(1-Nov-15\)](#)

[Omega-3-Acid Ethyl Esters \(1-Nov-15\)](#)

[Omega-3-Acid Ethyl Esters Capsules \(1-Nov-15\)](#)

[Oxycodone Hydrochloride \(1-Nov-15\)](#)

IN-PROCESS REVISION

[IPR Introduction](#)

GENERAL CHAPTERS

[<17> PRESCRIPTION CONTAINER LABELING \(USP39-NF34 1S\)](#)

[<476> CONTROL OF ORGANIC IMPURITIES IN DRUG SUBSTANCES AND DRUG PRODUCTS \(USP39-NF34 1S\)](#)

[<659> PACKAGING AND STORAGE REQUIREMENTS \(USP39-NF34 1S\)](#)

[<791> pH \(USP39-NF34 1S\)](#)

[<1035> BIOLOGICAL INDICATORS FOR STERILIZATION \(USP39-NF34 1S\)](#)

[<1058> ANALYTICAL INSTRUMENT QUALIFICATION \(USP39-NF34 1S\)](#)

[<1065> ION CHROMATOGRAPHY \(USP39-NF34 1S\)](#)

[<1086> IMPURITIES IN DRUG SUBSTANCES AND DRUG PRODUCTS \(USP39-NF34 1S\)](#)

[<1209> STERILIZATION—CHEMICAL AND PHYSICOCHEMICAL INDICATORS AND INTEGRATORS \(USP39-NF34 1S\)](#)

[<2251> ADULTERATION OF DIETARY SUPPLEMENTS WITH DRUGS AND DRUG ANALOGS \[NEW\] \(USP39-NF34 1S\)](#)

REAGENTS, INDICATORS, AND SOLUTIONS

Reagent Specifications

[2,6-Diaminopyridine \[NEW\] \(USP39-NF34 1S\)](#)

[Benzethonium Chloride \[NEW\] \(USP39-NF34 1S\)](#)

[Chelating Ion-Exchange Resin \[NEW\] \(USP39-NF34 1S\)](#)

Volumetric Solutions

[Benzethonium Chloride, Two Hundred Fiftieth-Molar \(0.004 M\) \[NEW\] \(USP39-NF34 1S\)](#)

Chromatographic Columns

[L## \(Eptacog Alfa, Dionex CarboPac PA100\) \[NEW\] \(USP39-NF34 1S\)](#)

[L## \(Eptacog Alfa, Dionex DNAPac PA100\) \[NEW\] \(USP39-NF34 1S\)](#)

[L## \(Metoprolol Succinate, Halo Penta-HILIC\) \[NEW\] \(USP39-NF34 1S\)](#)

[L26 \(USP39-NF34 1S\)](#)

IN-PROCESS REVISION

REFERENCE TABLES

Container Specifications

[Containers for Dispensing Capsules and Tablets \[NEW\] \(USP39-NF34 1S\)](#)

Description and Solubility

[Description and Solubility of USP and NF Articles \[NEW\] \(USP39-NF34 1S\)](#)

[Description and Solubility - E](#)

[Description and Solubility - N](#)

DIETARY SUPPLEMENT MONOGRAPHS

[Gamma-Aminobutyric Acid \[NEW\] \(USP39-NF34 1S\)](#)

[Glutathione \(USP39-NF34 1S\)](#)

[Krill Oil Capsules \(USP39-NF34 1S\)](#)

[Krill Oil Delayed-Release Capsules \(USP39-NF34 1S\)](#)

NF MONOGRAPHS

[Lecithin \(USP39-NF34 1S\)](#)

USP MONOGRAPHS

[Abacavir and Lamivudine Tablets \[NEW\] \(USP39-NF34 1S\)](#)

[Acetazolamide \(USP39-NF34 1S\)](#)

[Acetazolamide for Injection \(USP39-NF34 1S\)](#)

[Acetazolamide Tablets \(USP39-NF34 1S\)](#)

[Aminophylline \(USP39-NF34 1S\)](#)

[Aminophylline Injection \(USP39-NF34 1S\)](#)

[Aminophylline Oral Solution \(USP39-NF34 1S\)](#)

[Aminophylline Tablets \(USP39-NF34 1S\)](#)

[Argatroban \[NEW\] \(USP39-NF34 1S\)](#)

[Barium Hydroxide Lime \(USP39-NF34 1S\)](#)

[Biological Indicator for Dry-Heat Sterilization, Paper Carrier \(USP39-NF34 1S\)](#)

[Biological Indicator for Ethylene Oxide Sterilization, Paper Carrier \(USP39-NF34 1S\)](#)

[Biological Indicators for Moist Heat, Dry Heat, and Gaseous Modes of Sterilization, Liquid Spore Suspensions \(USP39-NF34 1S\)](#)

[Biological Indicators for Moist Heat, Dry Heat, and Gaseous Modes of Sterilization, Nonpaper](#)

[Carriers \(USP39-NF34 1S\)](#)
[Biological Indicator for Steam Sterilization, Paper Carrier \(USP39-NF34 1S\)](#)
[Biological Indicator for Steam Sterilization, Self-Contained \(USP39-NF34 1S\)](#)
[Bisotrizole \(USP39-NF34 1S\)](#)
[Bupivacaine Hydrochloride \(USP39-NF34 1S\)](#)
[Bupivacaine Hydrochloride Injection \(USP39-NF34 1S\)](#)
[Bupivacaine Hydrochloride in Dextrose Injection \(USP39-NF34 1S\)](#)
[Dantrolene Sodium \(USP39-NF34 1S\)](#)
[Dipyridamole \(USP39-NF34 1S\)](#)
[Dipyridamole Tablets \(USP39-NF34 1S\)](#)
[Eptacog Alfa \[NEW\] \(USP39-NF34 1S\)](#)
[Eptacog Alfa for Injection \[NEW\] \(USP39-NF34 1S\)](#)
[Exemestane \[NEW\] \(USP39-NF34 1S\)](#)
[Fluticasone Propionate Lotion \[NEW\] \(USP39-NF34 1S\)](#)
[Furosemide \(USP39-NF34 1S\)](#)
[Gemfibrozil Tablets \(USP39-NF34 1S\)](#)
[Interferon beta-1a \[NEW\] \(USP39-NF34 1S\)](#)
[Interferon beta-1a Injection \[NEW\] \(USP39-NF34 1S\)](#)
[lophendylate \(USP39-NF34 1S\)](#)
[lophendylate Injection \(USP39-NF34 1S\)](#)
[Levamisole Hydrochloride \(USP39-NF34 1S\)](#)
[Levetiracetam \(USP39-NF34 1S\)](#)
[Lithium Carbonate \(USP39-NF34 1S\)](#)
[Medroxyprogesterone Acetate Injectable Suspension \(USP39-NF34 1S\)](#)
[Medroxyprogesterone Acetate Tablets \(USP39-NF34 1S\)](#)
[Mesna \(USP39-NF34 1S\)](#)
[Methylprednisolone Sodium Succinate \(USP39-NF34 1S\)](#)
[Metoprolol Succinate \(USP39-NF34 1S\)](#)
[Metoprolol Succinate Extended-Release Tablets \(USP39-NF34 1S\)](#)
[Oxcarbazepine Tablets \(USP39-NF34 1S\)](#)
[Oxtriphylline Delayed-Release Tablets \(USP39-NF34 1S\)](#)
[Paricalcitol \(USP39-NF34 1S\)](#)
[Paricalcitol Capsules \[NEW\] \(USP39-NF34 1S\)](#)
[Penicillin G Potassium \(USP39-NF34 1S\)](#)
[Penicillin V Potassium \(USP39-NF34 1S\)](#)
[Sildenafil Tablets \[NEW\] \(USP39-NF34 1S\)](#)
[Sodium Chloride and Dextrose Tablets \(USP39-NF34 1S\)](#)
[Somatropin \(USP39-NF34 1S\)](#)
[Somatropin for Injection \(USP39-NF34 1S\)](#)
[Succinylcholine Chloride for Injection \(USP39-NF34 1S\)](#)

[Temozolomide \(USP39-NF34 1S\)](#)

[Theophylline \(USP39-NF34 1S\)](#)

[Sterile Purified Water \(USP39-NF34 1S\)](#)

[Sterile Water for Inhalation \(USP39-NF34 1S\)](#)

[Sterile Water for Injection \(USP39-NF34 1S\)](#)

[Sterile Water for Irrigation \(USP39-NF34 1S\)](#)

STAGE 4 HARMONIZATION

[Stage 4 Harmonization](#)

STIMULI TO THE REVISION PROCESS

[STIMULI TO THE REVISION PROCESS](#)

[Determination of Thermodynamic Solubility of Active Pharmaceutical Ingredients for Veterinary](#)

[Species: A New USP General Chapter](#)

[Performance Test for Parenteral Dosage Forms](#)